This document is a press release or investor relations update from Sanofi and Regeneron dated around July 2015, detailing clinical trial results, pricing, and regulatory milestones for the cholesterol drug Praluent. It announces a positive opinion from the European Medicine Agency and schedules an investor conference call for July 24, 2015. The document bears a 'HOUSE_OVERSIGHT' footer, suggesting it was part of a document production to Congress, likely related to pharmaceutical pricing or regulatory investigations, though it contains no direct mentions of Jeffrey Epstein or his associates in this specific page.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity